ADVERTISEMENT
Ponatinib Plus Blinatumomab Safe, Effective for Newly Diagnosed Philadelphia Chromosome-Positive ALL
Ponatinib and blinatumomab both have single-agent activity in Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL). The combination of these 2 active agents could be an effective chemotherapy-free strategy for patients with Ph+ ALL and may reduce the need for allogeneic stem cell transplantation in first remission.
In this video, Nicholas Short, MD, University of Texas MD Anderson Cancer Center, Houston, discusses findings from a phase 2 study that explored simultaneous ponatinib and blinatumomab in this patient population, showing the combination is safe and effective. These results were presented at the 2022 ASH Annual Meeting & Exposition in New Orleans, LA.
Source:
Short N, Kantarjian H, Jain N et al. Ponatinib and Blinatumomab for Patients with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Subgroup Analysis from a Phase II Study. Presented at the ASH Annual Meeting & Exposition; December 10-13, 2022; New Orleans, LA, and virtual. Abstract 213.
